



#301000
11/21/02

PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1637
)
Application Ser. No.: 08/475,822) Examiner: Jeffrey Norman Fredman
)
Filed: June 7, 1995)
)
For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF
LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS
ENCODED BY SAID LAV GENOMIC RNA

Commissioner for Patents
Washington, DC 20231

Sir:

TRANSMITTAL LETTER

Enclosed is a reply to the Office Action of October 2, 2002. The item(s) checked below are appropriate:

1. Petition for Extension of Time (1 page).
2. Response to Paper No. 29 (3 pages).
3. **\$110 Check for one-month extension fee is enclosed.**

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 18, 2002

By: Salvatore J. Arrigo

Salvatore J. Arrigo
Registration No. 46,083
Telephone: 202-408-4160
Facsimile: 202-408-4400
E-mail: arrigos@finnegan.com

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

#31128
11/21/02



PATENT
Customer No. 22,852
Attorney Docket No. 3495.0010-24

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Marc ALIZON et al.) Group Art Unit: 1637
)
Application Ser. No.: 08/475,822) Examiner: Jeffrey Norman Fredman
)
Filed: June 7, 1995)
)

For: CLONED DNA SEQUENCES RELATED TO THE GENOMIC RNA OF
LYMPHADENOPATHY-ASSOCIATED VIRUS (LAV) AND PROTEINS
ENCODED BY SAID LAV GENOMIC RNA

Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO PAPER NO. 29

In response to the Office communication dated October 2, 2002 (Paper No. 29),
the period for reply to which has been extended by filing a petition for a one-month
extension of time and fee concurrently herewith, applicants submit the following
remarks.

REMARKS

Reconsideration of this application is respectfully requested.

The Office found applicants reply filed September 3, 2002, not fully responsive
to the prior Office Action because applicants requested that the obviousness-type
double patenting rejection be held in abeyance. The Office indicated that this was not
a proper response and required applicants to either affirmatively state that a terminal

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP
1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

RECEIVED
NOV 20 2002
TECH CENTER 1600/2000